Casdin Capital, LLC Century Therapeutics, Inc. Transaction History
Casdin Capital, LLC
- $713 Million
- Q2 2025
A detailed history of Casdin Capital, LLC transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 1,228,190 shares of IPSC stock, worth $638,658. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,228,190
Previous 3,212,316
61.77%
Holding current value
$638,658
Previous $1.54 Million
55.42%
% of portfolio
0.1%
Previous 0.18%
Shares
6 transactions
Others Institutions Holding IPSC
# of Institutions
67Shares Held
23.8MCall Options Held
33.4KPut Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$2.81 Million0.91% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.11MShares$1.1 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.02MShares$1.05 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$886,2000.28% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $30.6M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...